FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood [Yahoo! Finance]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: Yahoo! Finance
On Thursday, the FDA approved Ionis Pharmaceuticals, Inc.'s (NASDAQ: IONS ) Tryngolza (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (SHTG) that can lead to acute pancreatitis (AP) SHTG is a condition where the level of triglycerides (type of fat) in the blood is more than three times the normal level. Tryngolza is the first-ever FDA-approved treatment that significantly and substantially reduces triglyceride levels in adults with FCS and provides a clinically meaningful reduction in AP events when used with an appropriate diet (=20 grams of fat per day). Tryngolza is self-administered via an auto-injector once-monthly. The FDA approval was based on Phase 3 Balance trial data in adult patients. In the Balance study, Tryngolza 80 mg demonstrated a statistically significant placebo-adjusted mean reduction in triglyceride levels of 42.5% from baseline to six m
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- Are Investors Undervaluing Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) By 30%? [Yahoo! Finance]Yahoo! Finance
- PANTHERx® Rare Selected by Ionis as Specialty Pharmacy for TRYNGOLZA™ (olezarsen) [Yahoo! Finance]Yahoo! Finance
- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.MarketBeat
- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "outperform" rating re-affirmed by analysts at William Blair.MarketBeat
- TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet [Yahoo! Finance]Yahoo! Finance
IONS
Earnings
- 11/6/24 - Beat
IONS
Sec Filings
- 12/26/24 - Form 4
- 12/20/24 - Form 8-K
- 11/14/24 - Form SC
- IONS's page on the SEC website